HLS Therapeutics (HLS) Competitors C$3.62 +0.02 (+0.56%) (As of 12/18/2024 05:28 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsHeadlinesInsider Trades HLS vs. WEED, CPH, ACB, FIRE, EPI, OGI, ICC, RIV, LEAF, and RXShould you be buying HLS Therapeutics stock or one of its competitors? The main competitors of HLS Therapeutics include Canopy Growth (WEED), Cipher Pharmaceuticals (CPH), Aurora Cannabis (ACB), Supreme Cannabis (FIRE), ESSA Pharma (EPI), Organigram (OGI), ICC Labs (ICC), RIV Capital (RIV), Leaf Mobile (LEAF), and BioSyent (RX). These companies are all part of the "drug manufacturers - specialty & generic" industry. HLS Therapeutics vs. Canopy Growth Cipher Pharmaceuticals Aurora Cannabis Supreme Cannabis ESSA Pharma Organigram ICC Labs RIV Capital Leaf Mobile BioSyent Canopy Growth (TSE:WEED) and HLS Therapeutics (TSE:HLS) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, dividends, media sentiment, earnings, profitability, analyst recommendations, valuation, community ranking and risk. Does the media prefer WEED or HLS? In the previous week, Canopy Growth and Canopy Growth both had 3 articles in the media. HLS Therapeutics' average media sentiment score of 0.81 beat Canopy Growth's score of 0.46 indicating that HLS Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Canopy Growth 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral HLS Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate WEED or HLS? Canopy Growth currently has a consensus target price of C$6.26, indicating a potential upside of 53.84%. HLS Therapeutics has a consensus target price of C$4.13, indicating a potential upside of 13.95%. Given Canopy Growth's higher possible upside, analysts plainly believe Canopy Growth is more favorable than HLS Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Canopy Growth 3 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.25HLS Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is WEED or HLS more profitable? HLS Therapeutics has a net margin of -40.90% compared to Canopy Growth's net margin of -259.94%. HLS Therapeutics' return on equity of -24.82% beat Canopy Growth's return on equity.Company Net Margins Return on Equity Return on Assets Canopy Growth-259.94% -87.26% -3.83% HLS Therapeutics -40.90%-24.82%-2.89% Which has more risk & volatility, WEED or HLS? Canopy Growth has a beta of 1.79, suggesting that its stock price is 79% more volatile than the S&P 500. Comparatively, HLS Therapeutics has a beta of 1.07, suggesting that its stock price is 7% more volatile than the S&P 500. Which has better valuation and earnings, WEED or HLS? HLS Therapeutics has lower revenue, but higher earnings than Canopy Growth. HLS Therapeutics is trading at a lower price-to-earnings ratio than Canopy Growth, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCanopy GrowthC$287.10M1.20-C$602.30M-C$7.91-0.51HLS TherapeuticsC$58.89M1.95-C$24.09M-C$1.01-3.58 Does the MarketBeat Community believe in WEED or HLS? Canopy Growth received 606 more outperform votes than HLS Therapeutics when rated by MarketBeat users. However, 65.38% of users gave HLS Therapeutics an outperform vote while only 62.08% of users gave Canopy Growth an outperform vote. CompanyUnderperformOutperformCanopy GrowthOutperform Votes64062.08% Underperform Votes39137.92% HLS TherapeuticsOutperform Votes3465.38% Underperform Votes1834.62% Do institutionals and insiders hold more shares of WEED or HLS? 9.4% of Canopy Growth shares are owned by institutional investors. Comparatively, 65.2% of HLS Therapeutics shares are owned by institutional investors. 0.2% of Canopy Growth shares are owned by company insiders. Comparatively, 0.4% of HLS Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. SummaryHLS Therapeutics beats Canopy Growth on 12 of the 17 factors compared between the two stocks. Ad Porter & CompanyForbes rich list released… #1 to be assassinated?Elon Musk has just exposed the “energy grift” of America in a recent tweet to his platform, X. And people are slowly starting to wake up to the Deep State’s lies.To get the full details on the fake “energy crisis” of America, watch this now Get HLS Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for HLS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HLS vs. The Competition Export to ExcelMetricHLS TherapeuticsDrug Manufacturers IndustryMedical SectorTSE ExchangeMarket CapC$115.08MC$1.10BC$5.03BC$5.61BDividend Yield4.30%3.13%4.81%5.75%P/E Ratio-3.58105.06133.0827.82Price / Sales1.952,087.151,119.691,253.90Price / Cash15.229.8240.6379.10Price / Book1.393.174.753.31Net Income-C$24.09MC$142.32MC$118.34MC$287.14M7 Day Performance-0.82%-1.13%11.41%-3.60%1 Month Performance12.77%-2.66%9.50%-0.41%1 Year Performance2.84%100.39%29.79%32.12% HLS Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HLSHLS Therapeutics2.0879 of 5 starsC$3.62+0.6%C$4.13+14.0%+4.0%C$115.08MC$58.89M-3.5891High Trading VolumeWEEDCanopy Growth1.2129 of 5 starsC$4.34-1.8%C$7.12+64.0%+516.7%C$368.29MC$287.10M-0.562,700Analyst DowngradeNews CoverageCPHCipher Pharmaceuticals0.5946 of 5 starsC$14.12-0.8%C$12.50-11.5%+126.8%C$361.33MC$22.16M11.395ACBAurora Cannabis0.4015 of 5 starsC$6.08-1.1%C$6.35+4.4%+869.8%C$332.33MC$278.98M-9.761,073Analyst ForecastNews CoverageFIRESupreme CannabisN/AC$0.34+3.0%N/AN/AC$259.40MC$53.29M-10.81400EPIESSA PharmaN/AC$8.20+7.2%N/A+0.0%C$237.87MN/A-8.2725OGIOrganigram3.2013 of 5 starsC$2.17+3.3%C$3.86+78.0%+20.0%C$235.60MC$149.21M-0.84987Analyst ForecastGap UpICCICC LabsN/AC$1.62-5.8%N/A+0.0%C$223.64MC$533,684.0095.29N/AGap UpRIVRIV CapitalN/AC$1.50-6.3%N/AN/AC$213.65MC$11.33M-1.6312LEAFLeaf MobileN/AC$2.59-1.9%N/AN/AC$198.42MC$83.74M58.86150RXBioSyentN/AC$11.89-0.8%N/A+32.3%C$137.81MC$33.82M19.97N/A Related Companies and Tools Related Companies Canopy Growth Competitors Cipher Pharmaceuticals Competitors Aurora Cannabis Competitors Supreme Cannabis Competitors ESSA Pharma Competitors Organigram Competitors ICC Labs Competitors RIV Capital Competitors Leaf Mobile Competitors BioSyent Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (TSE:HLS) was last updated on 12/19/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTop Picks for Trump’s Pro-Crypto AmericaCoins Set to Soar with a Pro-Crypto White House President-Elect Donald Trump is reported to be holding over...Crypto 101 Media | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding HLS Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share HLS Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
